Table 1

Summarises all patients of our study and includes demographical information, description and activity of the disease, and complications during treatment with IFN

Patient No	Centre*	Sex	Age	MS duration(years)	Uveitis duration (years)	Bilateral	Granulomatous changes?	Periphlebitis/vasculitis?	Optic neuritis	Immunosuppression before IFN	Duration of IFN treatment (months)	Total observation time (months)	Side effects from interferon
*H (Heidelberg), E (Essen), W (Vienna), T (Tübingen), M (Münster).
1	H	F	35	6.1	13.9	yes	no	yes	no	no	19.7	7.9	none
2	H	F	48	9.2	1.7	no	no	no	yes	no	25.6	25.9	minimal myopathy
3	H	M	38	8.2	26.2	yes	no	yes	no	no	20.7	18.7	none
4	H	F	51	13.2	4.0	yes	yes	yes	no	no	42.3	33.3	none
5	H	F	50	8.2	9.2	yes	yes	no	yes	methotrexate	17.7	11.2	none
6	E	F	58	5.3	4.0	yes	no	yes	yes	azathioprine	24.6	7.9	depression initially, tremor, restlessness
7	E	F	43	25.2	3.8	yes	yes	yes	yes	no	29.5	17.7	none
8	W	M	49	2.1	2.4	no	yes	no	yes	no	78.7	74.8	none
9	W	F	41	6.2	3.0	yes	yes	yes	yes	no	45.2	30.5	none
10	W	M	54	9.6	30.2	yes	no	yes	no	no	24.6	21.9	none
11	W	M	34	3.9	7.2	yes	no	yes	no	no	7.9	7.9	none
12	T	M	39	3.8	2.8	yes	yes	yes	no	no	28.7	22.7	none
13	M	F	48	17.2	5.3	yes	yes	yes	yes	no	18.1	17.8	dizziness